KR102886521B1 - 통증을 치료하기 위해 페녹시프로필아민 화합물을 사용하는 방법 - Google Patents

통증을 치료하기 위해 페녹시프로필아민 화합물을 사용하는 방법

Info

Publication number
KR102886521B1
KR102886521B1 KR1020217009800A KR20217009800A KR102886521B1 KR 102886521 B1 KR102886521 B1 KR 102886521B1 KR 1020217009800 A KR1020217009800 A KR 1020217009800A KR 20217009800 A KR20217009800 A KR 20217009800A KR 102886521 B1 KR102886521 B1 KR 102886521B1
Authority
KR
South Korea
Prior art keywords
pain
compound
subject
pharmaceutical composition
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217009800A
Other languages
English (en)
Korean (ko)
Other versions
KR20210061357A (ko
Inventor
레미 루트링거
나딘 노엘
제이 사우드
Original Assignee
미쓰비시 타나베 파마 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미쓰비시 타나베 파마 코퍼레이션 filed Critical 미쓰비시 타나베 파마 코퍼레이션
Publication of KR20210061357A publication Critical patent/KR20210061357A/ko
Application granted granted Critical
Publication of KR102886521B1 publication Critical patent/KR102886521B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020217009800A 2018-09-04 2019-09-04 통증을 치료하기 위해 페녹시프로필아민 화합물을 사용하는 방법 Active KR102886521B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862726800P 2018-09-04 2018-09-04
US62/726,800 2018-09-04
PCT/US2019/049492 WO2020101790A2 (en) 2018-09-04 2019-09-04 Methods of using a phenoxypropylamine compound to treat pain

Publications (2)

Publication Number Publication Date
KR20210061357A KR20210061357A (ko) 2021-05-27
KR102886521B1 true KR102886521B1 (ko) 2025-11-17

Family

ID=69641874

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217009800A Active KR102886521B1 (ko) 2018-09-04 2019-09-04 통증을 치료하기 위해 페녹시프로필아민 화합물을 사용하는 방법

Country Status (15)

Country Link
US (2) US11766430B2 (https=)
EP (1) EP3846812A2 (https=)
JP (2) JP7439096B2 (https=)
KR (1) KR102886521B1 (https=)
CN (1) CN112955145A (https=)
AU (2) AU2019381269B2 (https=)
BR (1) BR112021004030A2 (https=)
CA (1) CA3110652A1 (https=)
CL (1) CL2021000531A1 (https=)
GB (1) GB2591937B (https=)
IL (1) IL281166B2 (https=)
MA (1) MA53565A (https=)
MX (1) MX2021002590A (https=)
UA (1) UA129837C2 (https=)
WO (1) WO2020101790A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021026480A2 (pt) 2019-06-28 2022-02-08 Univ Texas Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer
JP2024520463A (ja) 2021-05-24 2024-05-24 メディコン ファーマシューティカルズ，インコーポレイテッド 化学療法誘発性末梢神経障害に関連する疼痛の処置
EP4272826A3 (en) * 2021-05-24 2024-01-17 Medicon Pharmaceuticals, Inc. Treating pain associated with diabetic peripheral neuropathy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165263A1 (en) * 2001-02-20 2002-11-07 T.G. Dinan Treatment of fibromyalgia and related fatigue syndromes using antagonists or paritcal agonists of 5HT1a receptors
WO2017205399A1 (en) * 2016-05-25 2017-11-30 Minerva Neurosciences, Inc. (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207343A (en) 1978-06-22 1980-06-10 Eli Lilly And Company 1-Phenyl-3-(substituted phenoxy)propylamines
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ES2244438T3 (es) * 1999-05-24 2005-12-16 Mitsubishi Pharma Corporation Compuestos de fenoxipropilamina.
ES2220582T3 (es) 1999-12-20 2004-12-16 Eli Lilly And Company Derivados de piperidina y su uso como antagonistas de receptor de serotonina.
DK1423168T3 (da) * 2001-09-03 2006-05-15 Newron Pharm Spa Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
SA08280759B1 (ar) 2007-01-10 2011-05-04 سولفاي فارماسوتيكالز بي . في مركبات من عوامل مضادة لشبيه القنب – cb1 ومكونات هيكلية من مثبطات إعادة إمتصاص السيروتونين بأندلابين أو فلوكسامين
TW201039815A (en) 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
RU2424799C1 (ru) 2010-03-29 2011-07-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" Способ коррекции депрессивных расстройств производными тиетан-1,1-диоксида в эксперименте
DK2948143T3 (da) 2013-01-24 2021-07-26 Minerva Neurosciences Inc Anvendelse af phenoxypropylaminforbindelser til behandling af depression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165263A1 (en) * 2001-02-20 2002-11-07 T.G. Dinan Treatment of fibromyalgia and related fatigue syndromes using antagonists or paritcal agonists of 5HT1a receptors
WO2017205399A1 (en) * 2016-05-25 2017-11-30 Minerva Neurosciences, Inc. (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders

Also Published As

Publication number Publication date
US11766430B2 (en) 2023-09-26
IL281166A (en) 2021-04-29
WO2020101790A3 (en) 2020-07-09
UA129837C2 (uk) 2025-08-20
US20200069672A1 (en) 2020-03-05
IL281166B1 (en) 2025-04-01
AU2025204043A1 (en) 2025-06-19
JP2024056875A (ja) 2024-04-23
WO2020101790A2 (en) 2020-05-22
GB2591937B (en) 2023-06-07
EP3846812A2 (en) 2021-07-14
US20240016790A1 (en) 2024-01-18
JP7439096B2 (ja) 2024-02-27
MX2021002590A (es) 2021-05-31
CA3110652A1 (en) 2020-05-22
GB202104738D0 (en) 2021-05-19
AU2019381269B2 (en) 2025-03-06
IL281166B2 (en) 2025-08-01
KR20210061357A (ko) 2021-05-27
BR112021004030A2 (pt) 2021-06-22
AU2019381269A1 (en) 2021-03-18
MA53565A (fr) 2021-07-14
CN112955145A (zh) 2021-06-11
GB2591937A (en) 2021-08-11
CL2021000531A1 (es) 2021-10-08
JP2021536506A (ja) 2021-12-27

Similar Documents

Publication Publication Date Title
US20240016790A1 (en) Methods of using a phenoxypropylamine compound to treat pain
KR20030040201A (ko) 급성 통증, 만성 통증 및/또는 신경병성 통증 및 편두통을치료하기 위한 약학 조성물
RS56523B1 (sr) Tapentadol za sprečavanje i lečenje depresije i anksioznosti
US20110034565A1 (en) Psycho-pharmaceuticals
CA2846454A1 (en) Synergistic combinations of pi3k- and mek-inhibitors
HU226555B1 (en) Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
CN108463224A (zh) sGC刺激剂用于胃肠功能障碍治疗的应用
CN110996949A (zh) 用于治疗行为改变的方法
CN105209445B (zh) 治疗运动障碍和相关病症的方法
WO2016042501A1 (en) Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
US20110244057A1 (en) Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
JP2018515547A (ja) オピオイドとｎ−アシルエタノールアミンの組み合わせ
RU2797615C2 (ru) Способы применения феноксипропиламинового соединения для лечения боли
TWI874362B (zh) 使用苯氧丙胺化合物治療疼痛的方法
CN110191706A (zh) 治疗利多卡因无效病症和低钾血病症的治疗方法
WO2007069925A2 (en) Non-neurotoxic recreational drugs and a method of treating recreational drug abuse
PL231163B1 (pl) Kombinacja i kompozycja farmaceutyczna do zastosowania w leczeniu i/lub zapobieganiu bólowi z powodu umiarkowanych do ciężkich neuralgii o różnorodnym umiejscowieniu
CA2780495A1 (en) Tivozanib and temsirolimus in combination
US20170349438A1 (en) Pharmaceutical formulations of nitrite and uses thereof
JP2020525548A (ja) 炎症反応を伴う疼痛状態における鎮痛のための末梢限局的二重作用性κおよびδオピオイドアゴニスト
JP2025087929A (ja) うつ病および／またはうつ状態の治療および／または予防用医薬
Hipkin et al. Opioid receptor antagonists for gastrointestinal dysfunction
JP2013049643A (ja) 選択的セロトニン再取り込み阻害薬の誘発嘔吐に対する制吐剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)